Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Abstract Background Leukemia stem cells (LSCs) are responsible for the initiation and perpetuation of acute myeloid leukemia (AML), and also represent leukemia relapse reservoirs with limited therapeutic approaches. Thus, additional treatment strategies are medical unmet needs to eliminate LSCs. Met...

Full description

Bibliographic Details
Main Authors: Haijun Zhao, Yuelong Jiang, Fusheng Lin, Mengya Zhong, Jinshui Tan, Yong Zhou, Long Liu, Guowei Li, Manman Deng, Bing Xu
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Experimental Hematology & Oncology
Subjects:
Leukemia stem and progenitor cells
Acute myeloid leukemia (AML)
Apatinib
Chidamide
VEGFR
Bcl2
Online Access:https://doi.org/10.1186/s40164-022-00282-1

Internet

https://doi.org/10.1186/s40164-022-00282-1

Similar Items